---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-276424"
form_type: "8-K"
ticker: "MDGL"
cik: "0001157601"
company_name: "MADRIGAL PHARMACEUTICALS, INC."
filed_at: "2022-11-03T23:59:59+00:00"
generated_at: "2026-06-22T08:03:59.140110+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Madrigal Q3 cash $153.2M; MAESTRO-NASH topline data on track for Q4 2022

## Summary
- Cash, equivalents and marketable securities $153.2M at Sep 30, 2022, down from $270.3M at Dec 31, 2021.
- R&D expenses $68.3M for Q3 2022 vs $54.9M in Q3 2021; G&A $12.1M vs $8.3M.
- Cash used in operations for nine months ended Sep 30, 2022 was $166.3M.
- Topline data from Phase 3 MAESTRO-NASH biopsy study expected in Q4 2022; NDA filing planned H1 2023.
- Two resmetirom oral abstracts accepted at AASLD Liver Meeting presenting cirrhosis and noninvasive data.

## SEC filing metadata
- accession: 0001193125-22-276424
- form_type: 8-K
- ticker: MDGL
- cik: 0001157601
- company_name: MADRIGAL PHARMACEUTICALS, INC.
- filed_at: 2022-11-03T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1157601/000119312522276424/0001193125-22-276424-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1157601/000119312522276424/d409333d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-276424
- JSON: https://secwatch.observer/filing/0001193125-22-276424.json
- Plain text: https://secwatch.observer/filing/0001193125-22-276424.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.